Broadfin Capital LLC trimmed its holdings in shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) by 60.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,034,103 shares of the company’s stock after selling 3,157,487 shares during the quarter. Broadfin Capital LLC owned about 3.09% of Aralez Pharmaceuticals worth $2,746,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of ARLZ. GSA Capital Partners LLP increased its position in Aralez Pharmaceuticals by 88.5% during the second quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock worth $731,000 after buying an additional 254,400 shares during the last quarter. Intrinsic Edge Capital Management LLC acquired a new position in Aralez Pharmaceuticals during the second quarter worth $270,000. KCG Holdings Inc. acquired a new position in Aralez Pharmaceuticals during the first quarter worth $310,000. Franklin Street Advisors Inc. NC increased its position in Aralez Pharmaceuticals by 67.5% during the second quarter. Franklin Street Advisors Inc. NC now owns 99,229 shares of the company’s stock worth $134,000 after buying an additional 40,000 shares during the last quarter. Finally, Salzhauer Michael increased its position in Aralez Pharmaceuticals by 4.5% during the second quarter. Salzhauer Michael now owns 106,293 shares of the company’s stock worth $144,000 after buying an additional 4,600 shares during the last quarter. 23.79% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/14/broadfin-capital-llc-has-2-75-million-holdings-in-aralez-pharmaceuticals-inc-arlz.html.
Aralez Pharmaceuticals Inc. (ARLZ) traded down 14.72% during midday trading on Friday, reaching $1.68. 1,591,715 shares of the company’s stock were exchanged. Aralez Pharmaceuticals Inc. has a 52 week low of $0.95 and a 52 week high of $5.49. The company’s market cap is $112.30 million. The firm has a 50-day moving average price of $1.68 and a 200 day moving average price of $1.48.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). The firm had revenue of $27.62 million for the quarter, compared to analyst estimates of $21.37 million. Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The firm’s revenue for the quarter was up 119.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. Analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.62) EPS for the current year.
Separately, Chardan Capital decreased their price target on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating for the company in a report on Thursday, August 10th.
Aralez Pharmaceuticals Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ).
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.